Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

There are conflicting data regarding baseline determinants of virological nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting antiretroviral treatment (ART). We evaluated the impact of different baseline variables in the RESPOND cohort.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Infect Dis

Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1537-6591

ISSN (Print): 1058-4838

Publication date (Electronic): Aug 22 2023

Volume: 77

Issue: 4

Affiliations

[1 ] Department of Internal Medicine, Infectious Diseases Unit, Complexo Hospitalario Universitario de Ferrol, Ferrol, SERGAS-A Coruña, Spain.

[2 ] Department of Biochemistry, Genetics and Immunology, Universidade de Vigo, Vigo, Spain.

[3 ] CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

[4 ] Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom.

[5 ] Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark.

[6 ] Department of HIV, Mortimer Market Centre, London, United Kingdom.

[7 ] Department of Medicine, Medical Unit Infectious Diseases, Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden.

[8 ] Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

[9 ] Austrian HIV Cohort Study, Medizinische Universität Innsbruck, Innsbruck, Austria.

[10 ] The Royal Free HIV Cohort Study, Royal Free Hospital, University College London, London, United Kingdom.

[11 ] San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy.

[12 ] Italian Cohort Naive Antiretrovirals (ICONA), ASST Santi Paolo e Carlo, Milano, Italy.

[13 ] AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort, HIV Monitoring Foundation, Amsterdam, The Netherlands.

[14 ] Division of Infectious Diseases, Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.

[15 ] Modena HIV Cohort, Università degli Studi di Modena, Modena, Italy.

[16 ] Nice HIV Cohort, Université Côte d´Azur et Centre Hospitalier Universitaire, Nice, France.

[17 ] PISCIS Cohort Study, Centre Estudis Epidemologics de ITS i VIH de Catalunya, Badalona, Spain.

[18 ] Medical Department, University Hospital Bonn, Bonn, Germany.

[19 ] Swedish InfCare HIV Cohort, Karolinska University Hospital, Stockholm, Sweden.

[20 ] CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.

[21 ] Georgian National AIDS Health Information System, Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.

[22 ] Frankfurt HIV Cohort Study, University Hospital Frankfurt, Goethe-University, Infectious Diseases Unit, Frankfurt, Germany.

[23 ] The Kirby Institute, University of New South Wales, Sydney, Australia.

[24 ] ViiV Healthcare, Research Triangle Park, North Carolina, USA.

[25 ] Gilead Sciences, Foster City, California, USA.

[26 ] Merck Sharp & Dohme, Luzern, Switzerland.

[27 ] European AIDS Treatment Group, Brussels, Belgium.

[28 ] Infectious Diseases Department, Odense University Hospital, Odense, Denmark.

[29 ] Group of Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, Vigo, SERGAS-UVigo, Spain.

[30 ] Infectious Diseases Division and Fight Infections Foundation, University Hospital Germans Trias i Pujol, Barcelona, Spain.

Article

Publisher Item ID: 7117426

DOI: 10.1093/cid/ciad219

PubMed ID: 37052343

SO-VID: 3f07f1f9-a544-4264-9f9f-341bdcb8739c

History

Keywords: virological failure,blip,integrase inhibitors,low-level viremia,residual viremia

Data availability:

Keywords: virological failure, blip, integrase inhibitors, low-level viremia, residual viremia

Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.

Read this article at

Abstract

Related collections

RNA drug delivery

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 4

Cited by 3